Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;51(3):655-679.
doi: 10.1016/j.ecl.2022.01.004. Epub 2022 Jul 8.

Safety of Statins and Nonstatins for Treatment of Dyslipidemia

Connie B Newman  1
Affiliations
Review

Safety of Statins and Nonstatins for Treatment of Dyslipidemia

Connie B Newman. Endocrinol Metab Clin North Am. 2022 Sep.

Abstract

This article reviews the safety of statins and non-statin medications for management of dyslipidemia. Statins have uncommon serious adverse effects: myopathy/ rhabdomyolysis, which resolve with statin discontinuation, and diabetes, usually in people with risk factors for diabetes. The CVD benefit of statins far exceeds the risk of diabetes. Statin myalgia, without CK elevation, is likely caused by muscle symptoms with another etiology, or the nocebo effect. Notable adverse effects of non-statin medicines include injection site reactions (alirocumab, evolocumab, inclisiran), increased uric acid and gout (bempedoic acid), atrial fibrillation/flutter (omega-3-fatty acids), and myopathy in combination with a statin (gemfibrozil).

Keywords: Bempedoic acid; Dyslipidemia; Ezetimibe; Nonstatins; PCSK9 inhibitors; Safety; Statins.

PubMed Disclaimer

MeSH terms

Substances